Blinding is meant to prevent expectations from shaping trial results. Psychedelic drugs make that unusually difficult because their acute effects can reveal who received the active treatment.
A study can be labelled double blind while participants and staff correctly infer assignment. This “functional unblinding” does not prove that a result is false, but it weakens confidence about how much of the difference was caused by the drug.
ARTICLE AT A GLANCE
01
Labels are not enough
A nominally double-blind design should be accompanied by evidence showing whether the blind was maintained.
02
Bias can run both ways
Active-group hope may increase reported benefit, while placebo-group disappointment may reduce it.
03
Design can reduce, not erase
Active controls, independent raters, expectancy measures and separation of staff roles can improve interpretation.
In this guide
What blinding is meant to do
In a blinded randomised trial, participants, clinicians or outcome assessors do not know the assigned condition. This reduces the chance that expectations, behaviour or scoring differ systematically between groups.
Different people can be blinded separately. A central outcome rater may remain unaware even when the participant and session monitor have guessed correctly.
Functional unblinding
Functional unblinding occurs when the experienced effects make assignment apparent without anyone formally revealing it. Visual changes, altered emotion and prolonged shifts in perception are difficult for an inactive placebo to imitate.
In the FDA’s analysis of the MAPP2 MDMA trial, most active-group participants said they were positive they had received active drug. The agency concluded that unblinding and expectation bias affected the observed treatment effects to some extent, although the size of that effect could not be quantified.
How the bias can enter
Participants who believe they received active treatment may expect improvement or describe symptoms differently. Those who think they received placebo may feel disappointed. Session staff who infer assignment may also behave differently or deliver later therapy with more optimism.
When outcomes rely on interviews and self-report, those pathways are especially important. Objective measures are not immune, but they may be less directly affected by expectancy.
Can an active placebo solve it?
Researchers sometimes use niacin, diphenhydramine, a stimulant or a very low psychedelic dose to create noticeable effects in the control group. An active control can make guessing harder, but it may not reproduce the quality or intensity of a full psychedelic experience.
A 2026 comparative randomised study of psilocybin, MDMA and methylphenidate in healthy volunteers found overall blinding was insufficient. Methylphenidate concealed MDMA better than psilocybin, illustrating that control performance depends on the active drug.
Measure the blind, do not assume it
Trials can ask participants, monitors and raters which condition they think was assigned, how certain they are and which experiences informed the guess. These questions should be timed carefully because repeated guessing can itself focus attention on assignment.
Reporting only the percentage of correct guesses can also mislead when group sizes or response options differ. Certainty and reasons add useful context.
What stronger designs can do
Useful safeguards include independent central raters, standardised support, separation between session monitors and later therapists, expectancy measurement, credible active controls and analysis plans written before results are known.
Factorial designs may help separate drug and psychotherapy components. Multiple doses can test a gradient, although low doses can have effects of their own. No single method completely removes the problem.
How readers should interpret the result
Do not discard every psychedelic trial simply because blinding is difficult. Instead, lower certainty when guesses were accurate, outcomes were subjective, group expectations differed or staff roles allowed bias to spread.
Confidence rises when findings replicate across teams, controls and populations; when raters remain blinded; and when benefits appear in functioning and durability as well as a single symptom score.
The honest answer
Psychedelic trials can be randomised and formally blinded, but strong subjective effects often break the blind in practice; good studies measure and manage that limitation.
Safety and scope
Unblinding is a research-design issue, not evidence that unsupervised use is safe or effective. It should change confidence in a result, not be used to make personal treatment decisions.
ARTICLE RECORD
- Editorial category: Evidence & Research
- Evidence status: Direct blinding assessments and regulator reviews show frequent functional unblinding; mitigation methods remain imperfect.
- Sources checked: 29 July 2026
- Independent clinical review: Not independently clinically reviewed.
Sources and further reading
- FDA final guidance: Psychedelic Drugs—Considerations for Clinical Investigations
- FDA review of NDA 215455: Functional unblinding analysis
- FDA advisory committee meeting summary, 4 June 2024
- Belinger et al. (2026): Comparative blinding integrity trial
- Muthukumaraswamy et al. (2021): Blinding and expectancy confounds
Editorial note: This article is for education and evidence literacy. It is not medical advice, a diagnosis, a recommendation to use a substance, or a substitute for care from a qualified professional.
